Treatment Patterns and Outcomes of Pediatric Chronic Myeloid Leukemia in a Brazilian Multicenter Cohort

This multicenter retrospective cohort study evaluated the treatment patterns and outcomes of 79 children and adolescents with chronic myeloid leukemia who were treated at eight Brazilian centers from 2000 to 2025. Most patients were diagnosed in chronic phase (90.7%) and received frontline imatinib (89.9). At 12 months, optimal molecular response was achieved in 86.5% of evaluable patients (45/52). Survival outcomes were favorable, with overall and event-free survival of 93.7% (74/79) and 72.1% (57/79), respectively. Notably, outcomes were comparable to international pediatric cohorts despite heterogeneous access to molecular monitoring and second-generation tyrosine kinase inhibitors.

Authors

Institutions

Publication Details

Journal
Pediatric Blood & Cancer
Published
2026-07-23
DOI
https://doi.org/10.1002/1545-5017.70553
Primary Topic
Chronic Myeloid Leukemia Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Treatment Patterns and Outcomes of Pediatric Chronic Myeloid Leukemia in a Brazilian Multicenter Cohort

Mecneide Mendes Lins, Vanuza Maria Rosa, Neviçolino Pereira de Carvalho Filho, Nathália Kersting et al.
Pediatric Blood & Cancer
Chronic Myeloid Leukemia Treatments
article

Treatment Patterns and Outcomes of Pediatric Chronic Myeloid Leukemia in a Brazilian Multicenter Cohort

Mecneide Mendes Lins, Vanuza Maria Rosa, Neviçolino Pereira de Carvalho Filho, Nathália Kersting, Sidnei Epelman, Terezinha de Jesus Marques-Salles, Priscila Monteiro, Ciliana Rechenmacher, Liane Esteves Daudt, Larissa Bueno Polis Moreira, M S da Silva, Mariana Bohns Michalowski, Rebeca Ferreira Marques, Daniela Dias Morales, Patrícia Moura, Rodrigo Pirih Pecoits, Kizy da Costa Corrêa, Vitória Flores dos Santos, Ana Virginia Lopes de Sousa
article en

Abstract

This multicenter retrospective cohort study evaluated the treatment patterns and outcomes of 79 children and adolescents with chronic myeloid leukemia who were treated at eight Brazilian centers from 2000 to 2025. Most patients were diagnosed in chronic phase (90.7%) and received frontline imatinib (89.9). At 12 months, optimal molecular response was achieved in 86.5% of evaluable patients (45/52). Survival outcomes were favorable, with overall and event-free survival of 93.7% (74/79) and 72.1% (57/79), respectively. Notably, outcomes were comparable to international pediatric cohorts despite heterogeneous access to molecular monitoring and second-generation tyrosine kinase inhibitors.

Pediatric Blood & Cancer
Universidade Federal do Rio Grande do Sul (BR), Fundação de Apoio a Pesquisa do Estado de Goiás (BR), Hospital Universitário de Santa Maria (BR), Support group for adolescents and children with cancer (BR), Hospital de Clínicas de Porto Alegre (BR), Instituto de Medicina Integral Professor Fernando Figueira (BR), Hospital Amaral Carvalho (BR), Hospital Araújo Jorge (BR), Hospital Universitário Oswaldo Cruz (BR), Instituto de Saúde (BR), Hospital Santa Marcelina (BR), Universidade do Vale do Rio dos Sinos (BR)
Good health and well-being
Openalex Percentile: Top 10%
Chronic Myeloid Leukemia Treatments
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.